Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 2, 2011, Pages 199-208

  Soussi, Thierry ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Cancer etiology; Molecular epidemiology; Mutation database; Novel generation sequencing; TP53 gene mutations

Indexed keywords

5 METHYLCYTOSINE; CPG OLIGODEOXYNUCLEOTIDE; PROTEIN P53;

BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; OBSERVATIONAL STUDY; ONCOGENE H RAS; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; RISK FACTOR; SKIN CANCER; TP53 GENE; TUMOR GENE;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; GENOME; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS;

EID: 79961110903     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.07.003     Document Type: Review

References (52)

1. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11:685-696.
2. McDermott U., Downing J.R., Stratton M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 2011, 364:340-350.
3. Green R.E., et al. A draft sequence of the Neandertal genome. Science 2010, 328:710-722.
4. Lo Y.M., et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2010, 2:61ra91.
5. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
6. Greenman C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
7. Haber D.A., Settleman J. Cancer: drivers and passengers. Nature 2007, 446:145-146.
8. Soussi T., Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007, 12:303-312.
9. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
10. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
11. Soussi T., Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 2003, 21:192-200.
12. Yamagiwa K., Ichikawa K. Experimental study of the pathogenesis of carcinoma. J. Cancer Res. 1918, 3:1-21.
13. Loeb L.A., Harris C.C. Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res. 2008, 68:6863-6872.
14. Luch A. Nature and nurture - lessons from chemical carcinogenesis. Nat. Rev. Cancer 2005, 5:113-125.
15. Brookes P., Lawley P.D. Evidence for the binding of polynuclear aromatic hydrocarbons to the nucleic acids of mouse skin: relation between carcinogenic power of hydrocarbons and their binding to deoxyribonucleic acid. Nature 1964, 202:781-784.
16. Ames B.N., Durston W.E., Yamasaki E., Lee F.D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. U. S. A. 1973, 70:2281-2285.
17. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., van Bodegom P.C., Bos J.L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988, 48:5738-5741.
18. Rountree M.R., Bachman K.E., Herman J.G., Baylin S.B. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001, 20:3156-3165.
19. Tornaletti S., Pfeifer G.P. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 1995, 10:1493-1499.
20. Bird A.P. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res. 1980, 8:1499-1504.
21. Stenson P.D., Ball E.V., Howells K., Phillips A.D., Mort M., Cooper D.N. The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum. Genomics 2009, 4:69-72.
22. Sjoblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
23. Parsons D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
24. McLendon R., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
25. Wynder E.L., Graham E.A. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J. Am. Med. Assoc. 1950, 143:329-336.
26. Proctor R.N. Tobacco and the global lung cancer epidemic. Nat. Rev. Cancer 2001, 1:82-86.
27. Boullin J.M. p53 tumour suppressor gene and the tobacco industry. Lancet 2005, 365:567.
28. Soussi T., Asselain B., Hamroun D., Kato S., Ishioka C., Claustres M., Beroud C. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin. Cancer Res. 2006, 12:62-69.
29. Cui F., Sirotin M.V., Zhurkin V.B. Impact of Alu repeats on the evolution of human p53 binding sites. Biol. Direct 2011, 6:2.
30. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001, 20:320-328.
31. Liu Z., Muehlbauer K.R., Schmeiser H.H., Hergenhahn M., Belharazem D., Hollstein M.C. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res. 2005, 65:2583-2587.
32. Davies H., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65:7591-7595.
33. Ding L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
34. Kan Z., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
35. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5:5-23.
36. Dolezalova H., Vojtesek B., Kovarik J. Epitope analysis of the human p53 tumour suppressor protein. Folia Biol. (Praha) 1997, 43:49-51.
37. Weigelt B., Geyer F.C., Reis-Filho J.S. Histological types of breast cancer: how special are they?. Mol. Oncol. 2010, 4:192-208.
38. Hartmann A., Blaszyk H., Kovach J.S., Sommer S.S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997, 13:27-33.
39. Stephens P.J., et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
40. Shah S.P., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
41. Ding L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
42. Brash D.E. Sunlight and the onset of skin cancer. Trends Genet. 1997, 13:410-414.
43. Brash D.E., Rudolph J.A., Simon J.A., Lin A., McKenna G.J., Baden H.P., Halperin A.J., Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:10124-10128.
44. Moles J.P., Moyret C., Guillot B., Jeanteur P., Guilhou J.J., Theillet C., Basset-Seguin N. p53 gene mutations in human epithelial skin cancers. Oncogene 1993, 8:583-588.
45. Dumaz N., Drougard C., Sarasin A., Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10529-10533.
46. Pleasance E.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
47. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. 2003, 21:201-216.
48. Berger M.F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
49. Bell D., et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
50. Chapman M.A., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
51. Chin L., Hahn W.C., Getz G., Meyerson M. Making sense of cancer genomic data. Genes Dev. 2011, 25:534-555.
52. Hudson T.J., et al. International network of cancer genome projects. Nature 2010, 464:993-998.